Portal Innovations is a Chicago-based venture capital firm and venture development platform that provides seed capital, fully equipped lab space, and mentorship to early-stage biotech, medtech, and life sciences startups. Founded in 2020, it invests in science-driven innovators, particularly those affiliated with universities.
46% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 3 prior). Their most common stage is series-a (54% of deals). Average disclosed round size is $14.9M (across 12 rounds with reported amounts).
Portfolio
10
Fund Size
$100M
Top Stage
Series A
Last 12 Mo
1
Team
Dr. Prasad
biotechnology analyst at William Blair
Dr. Porter
founder and CEO of Cellevolve Bio
Emily Yee
member of the Lab Ops team
Michael Reagan
Manager of Lab Operations for Portal Innovations
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Syntax | Series A | $14.4M | Jun 2026 |
| SSyntis Bio | Series A | $38M | Jul 2025 |
 Grove Biopharma | Series A | $30M | Apr 2025 |
 March Bio | Series A | $28.4M | Oct 2024 |
 Crossbridge Bio | Seed | $10M | Jan 2024 |
| SSyntis Bio | Seed | $15.5M | Jan 2023 |
 Cardiosense | Series A | $15.1M | Dec 2022 |
 Rhaeos | Seed | $2.2M | Dec 2021 |
 ClostraBio | Seed | $3.5M | Jan 2018 |
 Syntax Bio | Unknown | $14.4M | — |
 Moonlight Therapeutics | Seed | $3M | — |
| SSyntis Bio | Series A | — | — |
| ClostraBio | Series A | $4M | — |
Top Co-Investors
Last updated: 20 October 2026